LH
Labcorp Holdings Inc.
$281.48
-1.88
(-0.66%)
Mkt Cap
23.08B
Volume
520,237
52W Range
241.81-293.72
Sector
Healthcare
Beta
0.86
EPS (TTM)
11.37
P/E Ratio
24.76
Revenue (TTM)
14.14B
Rev Growth (5Y)
-0.0%
EPS Growth (5Y)
-8.0%
AlphaVal · Fair Value
What we estimate one share is worth
$239.72
Overvalued
moderate signal
17.4% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C
Stable Earnings Power
54.7 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.95B | 13.01B | 12.16B | 11.86B | 13.14B | 13.98B | 11.55B | 11.33B | 10.44B | 9.64B | 8.68B | 6.01B |
| Net Income | 876.50M | 746.00M | 418.00M | 1.28B | 2.38B | 1.56B | 823.80M | 883.70M | 1.27B | 732.10M | 436.90M | 511.20M |
| EPS | 10.54 | 8.89 | 4.80 | 14.04 | 24.58 | 15.99 | 8.41 | 8.71 | 12.39 | 7.14 | 4.42 | 6.03 |
| Free Cash Flow | 1.21B | 1.10B | 874.10M | 1.47B | 2.65B | 1.75B | 1.04B | 925.60M | 1.14B | 897.00M | 726.60M | 535.50M |
| FCF / Share | 14.50 | 13.06 | 10.04 | 16.18 | 27.40 | 18.02 | 10.67 | 9.13 | 11.17 | 8.75 | 7.35 | 6.31 |
| Operating CF | 1.64B | 1.59B | 1.33B | 1.96B | 3.11B | 2.14B | 1.44B | 1.31B | 1.46B | 1.18B | 982.40M | 739.00M |
| Total Assets | 18.39B | 18.38B | 16.73B | 20.16B | 20.39B | 20.07B | 18.02B | 16.19B | 16.57B | 14.25B | 14.29B | 7.30B |
| Total Debt | 7.20B | 7.27B | 5.95B | 6.25B | 6.34B | 6.76B | 7.11B | 6.06B | 6.76B | 5.85B | 6.36B | 3.03B |
| Cash & Equiv | 532.30M | 1.52B | 536.80M | 320.60M | 1.47B | 1.32B | 337.50M | 426.80M | 316.60M | 433.60M | 716.40M | 580.00M |
| Book Value | 8.62B | 8.05B | 7.88B | 10.10B | 10.27B | 9.44B | 7.57B | 6.97B | 6.80B | 5.51B | 4.95B | 2.82B |
| Return on Equity | 0.10 | 0.09 | 0.05 | 0.13 | 0.23 | 0.16 | 0.11 | 0.13 | 0.19 | 0.13 | 0.09 | 0.18 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.54B | 3.52B | 3.56B | 3.53B | 3.35B | 3.33B | 3.28B | 3.22B | 3.18B | 3.03B | 3.06B | 3.03B |
| Net Income | 277.80M | 164.70M | 261.10M | 237.90M | 212.80M | 143.40M | 169.30M | 205.30M | 228.00M | (167.10M) | 183.30M | 188.90M |
| EPS | 3.37 | 2.00 | 3.14 | 2.86 | 2.54 | 1.72 | 2.02 | 2.44 | 2.71 | -1.97 | 2.12 | 2.13 |
| Free Cash Flow | 70.50M | 490.30M | 280.50M | 542.70M | (107.50M) | 665.10M | 161.50M | 432.90M | (163.60M) | 412.40M | 170.60M | 237.80M |
| FCF / Share | 0.86 | 5.94 | 3.38 | 6.50 | -1.29 | 7.96 | 1.92 | 5.15 | -1.95 | 4.86 | 1.97 | 2.68 |
| Operating CF | 191.50M | 614.20M | 387.20M | 620.60M | 18.50M | 777.20M | 277.30M | 561.10M | (29.80M) | 579.60M | 275.50M | 341.10M |
| Total Assets | 19.09B | 18.39B | 18.26B | 18.06B | 17.60B | 18.38B | 18.61B | 16.71B | 16.53B | 16.73B | 16.89B | 17.71B |
| Total Debt | 7.24B | 7.21B | 7.22B | 6.55B | 6.52B | 7.27B | 7.72B | 5.98B | 5.97B | 5.95B | 6.33B | 6.21B |
| Cash & Equiv | 981.10M | 532.30M | 598.10M | 647.30M | 369.40M | 1.52B | 1.52B | 265.10M | 99.30M | 536.80M | 727.90M | 1.93B |
| Book Value | 8.73B | 8.62B | 8.70B | 8.47B | 8.31B | 8.05B | 8.17B | 8.01B | 7.96B | 7.88B | 7.87B | 8.79B |
| Return on Equity | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | -0.02 | 0.02 | 0.02 |
LH News
Labcorp Holdings Inc. $LH Stock Position Raised by D.A. Davidson & CO.
Labcorp Holdings: The Story Has Not Changed Materially
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
Labcorp Declares Quarterly Dividend
Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock
LH or CRL: Which Is the Better Value Stock Right Now?
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
Is it the Right Time to Add Labcorp Stock to Your Portfolio?
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test